<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795171</url>
  </required_header>
  <id_info>
    <org_study_id>MK URO 4</org_study_id>
    <secondary_id>EUDRACT 2007-003705-27</secondary_id>
    <nct_id>NCT00795171</nct_id>
  </id_info>
  <brief_title>Biomarker Study for Sunitinib and Docetaxel in Prostate Cancer</brief_title>
  <official_title>Randomized, Controlled Biomarker Study Evaluating the Anti-angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Docetaxel and sunitinib will be compared to docetaxel for their effect on CEC/CEP spikes
      induced by docetaxel in HRPC patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel (75mg/m2 q21d) is standard of care for patients with hormone refractory prostate
      cancer (HRPC). Recent data indicate, that chemotherapeutics given at MTD induce, besides
      their cytotoxic effects, mobilization of circulating endothelial cells (CEC) and -
      progenitors (CEP) in drug-free breaks of each cycle. In preclinical models, mobilized CEC/CEP
      result in tumor vasculogenesis and progression of disease.

      We hypothesize that treatment with sunitinib, an anti-angiogenic tyrosine kinase inhibitor,
      in between 3 weekly docetaxel disrupts CEC/CEP spikes following docetaxel leading to
      chemosensitization and reduced tumor re-growth in HRPC patients responding to docetaxel.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary: CEC/CEP spikes induced by MTD docetaxel in patients treated with docetaxel/sunitinib relative to docetaxel monotherapy</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate and length of treatment holidays relative to docetaxel monotherapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hormone Refractory Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taxotere</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 75mg/m2 day1 q 21d x 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel * Sunitinib</intervention_name>
    <description>docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles</description>
    <arm_group_label>Docetaxel + Sunitinib</arm_group_label>
    <other_name>Taxotere + Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel 75mg/m2 day1 q 21d x 4 cycles</description>
    <arm_group_label>Taxotere</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75mg/m2 q21d for 4 cycles</description>
    <arm_group_label>Taxotere</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WHO performance status of 0-2.

          -  Histologically proven prostate adenocarcinoma.

          -  All patients must have prostate adenocarcinoma that is unresponsive or refractory to
             androgen ablation with biochemical progression

          -  Measurable and/or evaluable progressive disease, which is defined by one of the
             following three criteria:

               -  25% increase in bidimensionally measurable soft tissue metastases

               -  Appearance of new metastatic lesions (proven by CT scan, X-ray or bone scan)

               -  PSA level of at least 10ng/mL, with increases on at least 2 successive occasions
                  at least 2 weeks apart

          -  If the patient has been treated with antiandrogens, treatment must have been stopped
             at least 6 weeks prior to study randomization

        Exclusion Criteria:

        - prior chemotherapy for prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael MK Krainer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Internal Medicine I, Medical University Vienna, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael MK Krainer, MD</last_name>
    <phone>+43 1 40400</phone>
    <phone_ext>4445</phone_ext>
    <email>michael.krainer@meduniwien.ac.at</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Internal Medicine</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker VW Wacheck, MD</last_name>
      <phone>+43 1 40400</phone>
      <phone_ext>2989</phone_ext>
      <email>Volker.Wacheck@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael , MK Krainer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>August 17, 2010</last_update_submitted>
  <last_update_submitted_qc>August 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dept of Internal Medicine I, Medical University Vienna, Austria</name_title>
    <organization>Medical University Vienna, Austria</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

